Track topics on Twitter Track topics that are important to you
Published on BioPortfolio: 2014-10-22T21:49:46-0400
This study will evaluate the relative bioavailability of 2 oral formulations of TKI258, and the effect of food on the bioavailability of TKI258, in adult patients with advanced solid tumor
This study will evaluate the efficacy of TKI258 in patients with advanced urothelial cancer
This study is an open-label, dose-escalating study to delineate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of TKI258. Pharmacokinetics and pharmacodynamics will be perfo...
The purpose of this phase II study of TKI258 (Dovitinib) in adenoid cystic carcinoma is to evaluate the efficacy of TKI258 (Dovitinib).
This study will evaluate safety and efficacy of TKI258 in patients with relapsed or refractory multiple myeloma
Cystic neoplasms of the liver are rare tumours. According to the recent WHO classification, they are classified into mucinous cystic neoplasm and intraductal papillary neoplasm based on the presence o...
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive neoplasm with leukemic features and frequent skin involvement. Translocations involving the MYC locus have been recently identifie...
Therapy related myeloid neoplasm (t-MN) is an emerging challenge in the current era. However, real world data on its incidence and survival at the population level remains sparse.
Cytotoxic chemotherapy has inherent mutagenic potential and alters the bone marrow microenvironment after therapy. In some cases, this potentiates expansion of an aberrant clone and may lead to a ther...
Although overall childhood cancer survival has improved, survivors may still have an elevated risk for second primary neoplasm (SPN) and excess mortality. The aim of the current study was to estimate ...
Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause.
The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Disappearance of a neoplasm or neoplastic state without the intervention of therapy.
Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.